相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Endogenous CD4+ thorn T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 (Her2) Driver Mutations
Joshua R. Veatch et al.
CANCER IMMUNOLOGY RESEARCH (2019)
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Elise Alspach et al.
NATURE (2019)
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer
Margaret L. Axelrod et al.
CLINICAL CANCER RESEARCH (2019)
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC
Bonnie L. Bullock et al.
LIFE SCIENCE ALLIANCE (2019)
Autophagy and MHC-restricted antigen presentation
Jan Valecka et al.
MOLECULAR IMMUNOLOGY (2018)
Evolutionary Pressure against MHC Class II Binding Cancer Mutations
Rachel Marty et al.
CELL (2018)
Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression
Jeff W. Kwak et al.
CANCER RESEARCH (2018)
Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling
In Ah Park et al.
PLOS ONE (2017)
The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade
Howard Y. Li et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Tumor Immunology meets. Immunology: Modified cancer cells as professional APC for priming naive tumor-specific CD4+T cells
Farah Bou Nasser Eddine et al.
ONCOIMMUNOLOGY (2017)
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
J. F. Novotny et al.
ANNALS OF ONCOLOGY (2016)
Cancer Statistics, 2016
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Expression Profiling of Macrophages Reveals Multiple Populations with Distinct Biological Roles in an Immunocompetent Orthotopic Model of Lung Cancer
Joanna M. Poczobutt et al.
JOURNAL OF IMMUNOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
Douglas B. Johnson et al.
NATURE COMMUNICATIONS (2016)
Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes
Andres Forero et al.
CANCER IMMUNOLOGY RESEARCH (2016)
The Non-Small Cell Lung Cancer Immune Contexture A Major Determinant of Tumor Characteristics and Patient Outcome
Romain Remark et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Sebastian Kreiter et al.
NATURE (2015)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
Jiabei He et al.
SCIENTIFIC REPORTS (2015)
The ins and outs of MHC class II-mediated antigen processing and presentation
Paul A. Roche et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
HLA Class II Antigen Expression in Colorectal Carcinoma Tumors as a Favorable Prognostic Marker
Giuseppe Sconocchia et al.
NEOPLASIA (2014)
T-helper-1-cell cytokines drive cancer into senescence
Heidi Braumueller et al.
NATURE (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Depletion of Cytosolic Phospholipase A2 in Bone Marrow-Derived Macrophages Protects against Lung Cancer Progression and Metastasis
Mary C. M. Weiser-Evans et al.
CANCER RESEARCH (2009)
Differential expression of MHC class II molecules in highly metastatic breast cancer cells is mediated by the regulation of the CIITA transcription - Implication of CIITA in tumor and metastasis development
B Shi et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2006)
Specificity and expression of CIITA, the master regulator of MHC class II genes
S LeibundGut-Landmann et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2004)
Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis
T Lovig et al.
BRITISH JOURNAL OF CANCER (2002)
The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues
PY Arnold et al.
JOURNAL OF IMMUNOLOGY (2002)
分享论文
